Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1967 1
1968 4
1969 5
1970 2
1971 2
1972 1
1974 1
1975 5
1976 1
1977 2
1978 3
1979 3
1982 1
1983 5
1984 4
1985 2
1986 3
1987 6
1988 1
1989 8
1990 7
1991 16
1992 9
1993 8
1994 14
1995 15
1996 20
1997 21
1998 37
1999 40
2000 33
2001 42
2002 58
2003 83
2004 109
2005 121
2006 130
2007 178
2008 158
2009 200
2010 195
2011 195
2012 207
2013 251
2014 257
2015 264
2016 256
2017 232
2018 233
2019 239
2020 216
2021 229
2022 169
2023 156
2024 166
2025 179
2026 91

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,263 results

Results by year

Filters applied: . Clear all
Page 1
Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes.
Hadjadj S, Rosenstock J, Meinicke T, Woerle HJ, Broedl UC. Hadjadj S, et al. Diabetes Care. 2016 Oct;39(10):1718-28. doi: 10.2337/dc16-0522. Epub 2016 Aug 4. Diabetes Care. 2016. PMID: 27493136 Clinical Trial.
OBJECTIVE: This study compared the efficacy and safety of initial combinations of empagliflozin + metformin with empagliflozin and metformin monotherapy in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: The study randomized 1,364 drug-naive patients (Hb …
OBJECTIVE: This study compared the efficacy and safety of initial combinations of empagliflozin + metformin with empagliflozin and …
Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial.
Mueller NT, Differding MK, Zhang M, Maruthur NM, Juraschek SP, Miller ER 3rd, Appel LJ, Yeh HC. Mueller NT, et al. Diabetes Care. 2021 Jul;44(7):1462-1471. doi: 10.2337/dc20-2257. Epub 2021 May 18. Diabetes Care. 2021. PMID: 34006565 Free PMC article. Clinical Trial.
Effects were similar in comparison of the metformin group with the behavioral weight loss group. Metformin versus control also increased butyrate, acetate, and valerate at 6 months (but not at 12 months). ...Future research is needed to elucidate whether the gut mic …
Effects were similar in comparison of the metformin group with the behavioral weight loss group. Metformin versus control also …
Metformin versus insulin for the treatment of gestational diabetes.
Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. Rowan JA, et al. N Engl J Med. 2008 May 8;358(19):2003-15. doi: 10.1056/NEJMoa0707193. N Engl J Med. 2008. PMID: 18463376 Free article. Clinical Trial.
RESULTS: Of the 363 women assigned to metformin, 92.6% continued to receive metformin until delivery and 46.3% received supplemental insulin. ...There were no serious adverse events associated with the use of metformin. CONCLUSIONS: In women with gestational …
RESULTS: Of the 363 women assigned to metformin, 92.6% continued to receive metformin until delivery and 46.3% received supple …
Comparison of the effects of empagliflozin and sitagliptin, as an add-on to metformin, on cardio-metabolic and glycemic parameters of patients with type 2 diabetes mellitus: a randomized, double-blind clinical trial.
Mesri Alamdari N, Barghaman M, Roshanravan N, Mobasseri M, Tutunchi H, Baharami A, Aliasgarzadeh A, Sadra V. Mesri Alamdari N, et al. BMC Res Notes. 2025 Jul 31;18(1):339. doi: 10.1186/s13104-025-07214-2. BMC Res Notes. 2025. PMID: 40745313 Free PMC article. Clinical Trial.
RESULTS: The significant changes in FBS from baseline to week 12 were - 23.1, -16.15, and - 15.25 mg/dl in the empagliflozin, sitagliptin, and metformin arm, respectively. HbA1C decreased significantly from baseline to week 12 in the empagliflozin, sitagliptin, and metf …
RESULTS: The significant changes in FBS from baseline to week 12 were - 23.1, -16.15, and - 15.25 mg/dl in the empagliflozin, sitagliptin, a …
Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial.
Lee JE, Yu SH, Kim SR, Ahn KJ, Song KH, Lee IK, Shon HS, Kim IJ, Lim S, Kim DM, Chung CH, Lee WY, Lee SH, Kim DJ, Cho SR, Jung CH, Jeon HJ, Lee SH, Park KY, Rhee SY, Kim SG, Park SO, Kim DJ, Kim BJ, Lee SA, Kim YH, Kim KS, Seo JA, Nam-Goong IS, Lee CW, Kim DK, Kim SW, Cho CG, Kim JH, Kim YJ, Yoo JM, Min KW, Lee MK. Lee JE, et al. Diabetes Metab J. 2024 Jul;48(4):730-739. doi: 10.4093/dmj.2023.0077. Epub 2024 May 20. Diabetes Metab J. 2024. PMID: 38763510 Free PMC article. Clinical Trial.
One hundred eighty-five eligible subjects were randomized to the combination group (metformin+atorvastatin), metformin group (metformin+atorvastatin placebo), and atorvastatin group (atorvastatin+metformin placebo). ...This study also suggested metf …
One hundred eighty-five eligible subjects were randomized to the combination group (metformin+atorvastatin), metformin group ( …
Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: A randomized, controlled, prospective study.
Wu Z, Zhang B, Chen F, Xia R, Zhu D, Chen B, Lin A, Zheng C, Hou D, Li X, Zhang S, Chen Y, Hou K. Wu Z, et al. Front Cell Infect Microbiol. 2023 Jan 4;12:1089991. doi: 10.3389/fcimb.2022.1089991. eCollection 2022. Front Cell Infect Microbiol. 2023. PMID: 36704100 Free PMC article. Clinical Trial.
METHODS: A total of 31 patients with newly diagnosed T2DM were randomized to intervention by metformin, FMT, or FMT plus metformin in the study. Patients were followed up at baseline and week 4 after treatment. Blood and stool samples were collected and subject to a …
METHODS: A total of 31 patients with newly diagnosed T2DM were randomized to intervention by metformin, FMT, or FMT plus metformin …
Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.
Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Garber AJ, et al. Am J Med. 1997 Dec;103(6):491-7. doi: 10.1016/s0002-9343(97)00254-4. Am J Med. 1997. PMID: 9428832 Free article. Clinical Trial.
After a 3-week, single-blind, placebo-controlled washout, 451 patients with fasting plasma glucose levels of at least 180 mg/dL were randomized to receive an 11-week course of placebo or metformin given at 500, 1000, 1500, 2000, or 2500 mg daily. RESULTS: Metformin …
After a 3-week, single-blind, placebo-controlled washout, 451 patients with fasting plasma glucose levels of at least 180 mg/dL were randomi …
Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug.
Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, Ståhlman M, Olsson LM, Serino M, Planas-Fèlix M, Xifra G, Mercader JM, Torrents D, Burcelin R, Ricart W, Perkins R, Fernàndez-Real JM, Bäckhed F. Wu H, et al. Nat Med. 2017 Jul;23(7):850-858. doi: 10.1038/nm.4345. Epub 2017 May 22. Nat Med. 2017. PMID: 28530702 Clinical Trial.
Recent evidence implicates the gut microbiota as a site of metformin action. In a double-blind study, we randomized individuals with treatment-naive T2D to placebo or metformin for 4 months and showed that metformin had strong effects on the gut microbiome. . …
Recent evidence implicates the gut microbiota as a site of metformin action. In a double-blind study, we randomized individuals with …
Analysis of Long-term Follow-up of a Randomized Clinical Trial With Departures From Assigned Treatments: Estimation of Metformin Effects on Diabetes and Its Complications in the Diabetes Prevention Program Outcomes Study.
Knowler WC, Pan Q, Shu S, Tripputi MT, Dabelea D, Edelstein SL, Kahn SE, Kuo S, Luchsinger JA, Shah V, Wallia A, Temprosa M; Diabetes Prevention Program Research Group. Knowler WC, et al. Diabetes Care. 2025 Oct 1;48(10):1668-1675. doi: 10.2337/dci25-0032. Diabetes Care. 2025. PMID: 40857175 Free PMC article. Clinical Trial.
Diabetes development led to changes in metformin treatment and addition of other glucose-lowering therapies. Using statistical methods designed to estimate intervention effects despite these deviations, we consistently found that metformin reduced diabetes incidence …
Diabetes development led to changes in metformin treatment and addition of other glucose-lowering therapies. Using statistical method …
Trial of restarting and tolerating metformin (TreatMet).
Orloff JN, Touhamy SH, Truong W, Casper A, Shukla AP, Igel LI, Flory JH. Orloff JN, et al. Diabetes Obes Metab. 2020 Nov;22(11):2189-2192. doi: 10.1111/dom.14137. Epub 2020 Jul 29. Diabetes Obes Metab. 2020. PMID: 32639649 Clinical Trial.
This randomized, double-blind, placebo-controlled, n-of-1 crossover study assessed whether metformin's side effects are reproducible in patients with a history of metformin intolerance. ...Two out of 10 participants adhered to a higher dose of metformin …
This randomized, double-blind, placebo-controlled, n-of-1 crossover study assessed whether metformin's side effects are reprod …
4,263 results